Tags : Third

Insights+

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More

Pharma

Merck and Eisai’s Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA’s

Shots: The third BT designation is based on P-Ib KEYNOTE-524 study assessing Keytruda (200mg, IV, q3w) + Lenvima (12/8 mg/day) in patients with unresectable HCC not amenable to locoregional treatment The dual regimen has received its first two BT designation for advanced and metastatic renal carcinoma and non-microsatellite instability-high/proficient mismatch repair endometrial carcinoma in Jan’18 […]Read More